COVID drug trial halted after failing to show benefit
Disease control
Terminated
This study tested whether adding the drug ABX464 to standard COVID-19 care could reduce dangerous inflammation and prevent patients from developing severe breathing problems. It involved 509 adults aged 65+ or younger adults with risk factors like obesity or diabetes. The trial w…
Phase: PHASE2, PHASE3 • Sponsor: Abivax S.A. • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC